184 related articles for article (PubMed ID: 33799598)
1. Bioluminescence Measurement of Time-Dependent Dynamic Changes of CYP-Mediated Cytotoxicity in CYP-Expressing Luminescent HepG2 Cells.
Iwado S; Abe S; Oshimura M; Kazuki Y; Nakajima Y
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799598
[TBL] [Abstract][Full Text] [Related]
2. Development of Caco-2 cells expressing four CYPs via a mammalian artificial chromosome.
Ohta Y; Kazuki K; Abe S; Oshimura M; Kobayashi K; Kazuki Y
BMC Biotechnol; 2020 Aug; 20(1):44. PubMed ID: 32819341
[TBL] [Abstract][Full Text] [Related]
3. Continuous long-term cytotoxicity monitoring in 3D spheroids of beetle luciferase-expressing hepatocytes by nondestructive bioluminescence measurement.
Yasunaga M; Fujita Y; Saito R; Oshimura M; Nakajima Y
BMC Biotechnol; 2017 Jun; 17(1):54. PubMed ID: 28637431
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies.
Satoh D; Iwado S; Abe S; Kazuki K; Wakuri S; Oshimura M; Kazuki Y
PLoS One; 2017; 12(10):e0187072. PubMed ID: 29065189
[TBL] [Abstract][Full Text] [Related]
5. Bioluminescence-based cytotoxicity assay for simultaneous evaluation of cell viability and membrane damage in human hepatoma HepG2 cells.
Uno K; Murotomi K; Kazuki Y; Oshimura M; Nakajima Y
Luminescence; 2018 May; 33(3):616-624. PubMed ID: 29424036
[TBL] [Abstract][Full Text] [Related]
6. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
[TBL] [Abstract][Full Text] [Related]
7. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
8. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
[TBL] [Abstract][Full Text] [Related]
9. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
[TBL] [Abstract][Full Text] [Related]
10. Correlation between luminescence intensity and cytotoxicity in cell-based cytotoxicity assay using luciferase.
Wakuri S; Yamakage K; Kazuki Y; Kazuki K; Oshimura M; Aburatani S; Yasunaga M; Nakajima Y
Anal Biochem; 2017 Apr; 522():18-29. PubMed ID: 28111305
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
13. Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4.
Yoo SE; Yi M; Kim WY; Cho SA; Lee SS; Lee SJ; Shin JG
Drug Metab Pharmacokinet; 2019 Jun; 34(3):201-208. PubMed ID: 30992242
[TBL] [Abstract][Full Text] [Related]
14. Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment.
Tolosa L; Donato MT; Pérez-Cataldo G; Castell JV; Gómez-Lechón MJ
Toxicol In Vitro; 2012 Dec; 26(8):1272-7. PubMed ID: 22138474
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
Bahar MA; Setiawan D; Hak E; Wilffert B
Pharmacogenomics; 2017 May; 18(7):701-739. PubMed ID: 28480783
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of genipin on human cytochrome P450 isoenzymes and P-glycoprotein in vitro.
Gao LN; Zhang Y; Cui YL; Yan K
Fitoterapia; 2014 Oct; 98():130-6. PubMed ID: 25073096
[TBL] [Abstract][Full Text] [Related]
18. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin.
Ghose R; Mallick P; Taneja G; Chu C; Moorthy B
Methods Mol Biol; 2016; 1395():55-68. PubMed ID: 26910068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
